Press release from Artimplant's Nomination Committee

Press release from Artimplant's Nomination Committee

Västra Frölunda, Sweden, March 11, 2008

In advance of Artimplant's Annual Meeting of Stockholders on May 6, 2008,
Artimplant's Nomination Committee has decided to propose that Ingemar Kihlström,
Lennart Ribohn, Anna Malm Bernsten and Wenche Rolfsen be re-elected as members
of the Board of Directors. Rickard Söderberg declines re-election. The
Nomination Committee has also decided to propose Mats Lindquist as a new member.

Mats Lindquist is Vice President, Global Business Development, NovaQuest.
NovaQuest is the Partnering Group of Quintiles Transnational. Quintiles is a
global CRO (Contract Research Organisation) with its core activities focused on
clinical development and commercialization of pharmaceutical products. Mats
Lindquist is a non executive Board member of BioPhausia AB.





For additional information, please contact: 
Ingemar Kihlström, Chairman, phone +46 733-82 11 02 

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on March 11, 2008 at 08:45 AM.